证券代码：688739 证券简称：成大生物 辽宁成大生物股份有限公司 投资者关系活动记录表 编号：2022-005 | --- | --- | --- | --- | --- | |-------------------------|--------------------------------|---------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------| | | | | | | | | | | | | | | | □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 | | | | 投资者关系活 | □新闻发布会 □路演活动 | | □现场参观 □电话会议 | | | 动类别 | | ■网络会议 □其他（请文字说明其他活动内容） | | | | 参与单位名称 及人员姓名 | | 华泰证券、国盛证券、平安养老、兴业 ...

2022 年第三季度报告 证券代码：688739 证券简称：成大生物 辽宁成大生物股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中 财务信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|---------------------------------------|------------------|------------------------------------------- ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 15%[1]. - The net profit attributable to shareholders was RMB 100 million, with a growth rate of 20% compared to the same period last year[1]. - The company's operating revenue for the first half of 2022 was CNY 881,304,926.41, a decrease of 24.83% compared to CNY 1,172,443,007.72 in the same period last year[26]. - Net profit attributable to shareholders for the first half of 2022 was CNY 381,065,445.03, down 33.78% from CNY 575,486,681.86 year-on-year[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 334.01 million yuan, a decline of 40.11% year-on-year[104]. - The company achieved operating revenue of 881.30 million yuan, a year-on-year decrease of 24.83%[104]. - The net profit attributable to the parent company was 381.07 million yuan, down 33.78% year-on-year[104]. - Operating cash flow increased by 62.90% to 172.71 million yuan[66]. Research and Development - The company is investing RMB 50 million in R&D for innovative vaccine technologies, focusing on enhancing efficacy and safety[1]. - The R&D investment as a percentage of operating revenue increased to 17.16%, up 4.41 percentage points from 12.75% in the previous year[26]. - The total R&D investment amounted to approximately ¥151.25 million, representing a year-on-year increase of 1.18%[52]. - The company has established three major R&D technology platforms for bacterial vaccines, viral vaccines, and multi-valent vaccines, with over 20 vaccine varieties under development[34]. - The company is currently conducting 14 research projects, with the most significant being the 15-valent HPV vaccine, which has a total expected investment of ¥100,000,000 and is in the process of obtaining clinical trial approval[55]. - The company has established a VLP technology platform that enhances the immunogenicity and safety of vaccines, particularly for HPV and hepatitis B vaccines[46]. - The company’s R&D expenses increased by 2.53% compared to the previous year, with a total of ¥114.92 million in expensed R&D[52]. Market Strategy and Expansion - Future outlook includes an expected revenue growth of 30% for the second half of 2022, driven by new product launches and market expansion[1]. - Market expansion strategies include entering Southeast Asian markets, targeting a revenue contribution of 5% from these regions by 2023[1]. - The company plans to launch two new vaccine products by the end of 2022, aiming to capture a 10% market share in the new segments[1]. - The company is focusing on innovative immunization schedules, such as the Zagreb 2-1-1 regimen for rabies vaccination, which reduces the number of visits and doses required[60]. Risk Management - Risk factors identified include regulatory changes and competition, with mitigation strategies outlined in the report[1]. - The company is facing risks due to a relatively single product structure, primarily relying on human rabies and inactivated Japanese encephalitis vaccines for revenue and profit[82]. - The company is actively managing accounts receivable risks by enforcing a strict customer admission system and credit evaluation process to mitigate potential losses from defaults[88]. - The company is closely monitoring macroeconomic conditions to mitigate investment risks and ensure compliance with investment regulations[92]. Environmental and Compliance - The company has established a comprehensive environmental management system and obtained GB/T 24001-2016/ISO14001:2015 certification[144]. - The company has implemented a wastewater treatment system that meets discharge standards, with regular monitoring of pollutants[133]. - The company is classified as a key pollutant discharge unit and adheres to environmental regulations, ensuring all emissions meet national standards[132]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[140]. Corporate Governance and Shareholder Relations - The company has established a profit distribution policy prioritizing cash dividends, with a minimum cash distribution of 10% of the annual distributable profit if there are no major investment plans[176]. - The company commits to a gradual reduction of shares post-lockup period, adhering to relevant regulations and ensuring the reduction price is not lower than the IPO price[169]. - The company will ensure that any related party transactions are conducted at fair market prices and will disclose necessary information as required by regulations[187]. - The company has outlined specific conditions under which the lock-up period may be extended[156].

2022 年第一季度报告 单位：元 币种：人民币 证券代码：688739 证券简称：成大生物 辽宁成大生物股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期 增减变动幅度 (%) | | 营业收入 | 366,344,805.12 | ...

Financial Performance - The company achieved a net profit attributable to shareholders of the parent company of ¥892,490,658.44 in 2021, with a total profit available for distribution to shareholders of ¥892,229,814.14 after statutory surplus reserve allocation[8]. - A cash dividend of ¥10 per 10 shares (including tax) is proposed, totaling ¥416,450,000, which accounts for 46.66% of the net profit attributable to shareholders of the parent company for 2021[8]. - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 15%[26]. - The company achieved operating revenue of CNY 2,088,043,469.78 in 2021, representing a year-on-year increase of 4.63%[33]. - The net profit attributable to shareholders was CNY 892,490,658.44, a decrease of 2.80% compared to the previous year[37]. - The net profit after deducting non-recurring gains and losses was CNY 862,518,502.00, reflecting a year-on-year increase of 2.13%[37]. - The net cash flow from operating activities was CNY 506,376,172.18, down 41.09% year-on-year, primarily due to delayed customer payments caused by the COVID-19 pandemic[37]. - The company's total assets reached CNY 9,792,731,456.06 at the end of 2021, an increase of 118.67% compared to the end of 2020[38]. - The net assets attributable to shareholders increased to CNY 9,352,015,548.09, marking a growth of 127.09% year-on-year[38]. - Basic earnings per share decreased by 4.49% to CNY 2.34 in 2021[36]. Research and Development - The R&D expenditure accounted for 14.91% of operating revenue, an increase of 3.77 percentage points compared to the previous year[36]. - The company has established three major R&D technology platforms, with over 20 vaccine varieties currently under research, including innovative and multi-valent vaccines[66]. - The company’s total R&D investment for the year reached ¥311,399,620.91, representing a year-on-year increase of 40.04% and accounting for 14.91% of the company's operating revenue[112][113]. - The company filed 17 new intellectual property applications during the reporting period, including 9 invention patent applications, and received 3 patent grants[111]. - The number of R&D personnel increased to 170, up from 155 in the previous year, with R&D personnel accounting for 11.12% of the total workforce[121]. - The company is currently conducting clinical trials for several vaccines, including the quadrivalent influenza vaccine, which is in Phase III trials with a total investment of ¥29,800,000[117]. - The company is actively expanding its R&D efforts, with a focus on new product development and clinical trials for various vaccines[113][117]. - The company has established three distinct technology platforms for vaccine development: bacterial vaccines, viral vaccines, and multi-valent vaccines, aligning with industry trends[102]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 25% market share by 2025[26]. - The company has completed the acquisition of a local biotech firm, which is expected to enhance its R&D capabilities and product pipeline[26]. - The company is enhancing its management system post-listing, focusing on risk prevention and talent recruitment to support future development[62]. - The company is committed to increasing R&D investment to mitigate long-term technology iteration risks and ensure the leading position of its core technology[129]. - The company is focusing on expanding its product portfolio to reduce risks associated with a relatively single product structure, particularly in rabies and encephalitis vaccines[135]. Operational Challenges and Risks - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[12]. - The company has not violated decision-making procedures for external guarantees[12]. - The company has not faced any issues with more than half of the directors being unable to ensure the authenticity, accuracy, and completeness of the annual report[12]. - The company is closely monitoring macroeconomic conditions to manage investment risks effectively[145]. - The company faces potential foreign exchange risks due to international sales and purchases, which could impact financial performance[148]. - The company is increasing R&D investments to address the risk of declining demand for human rabies vaccines in the long term[149]. Product Development and Innovation - The company is currently developing a new mRNA vaccine, expected to enter clinical trials by Q3 2022[26]. - The approval for clinical trials of the 15-valent HPV vaccine was received in December 2021, marking a significant breakthrough in innovative vaccine projects[53]. - The company is advancing the development of new technologies and processes for its existing vaccines, including the human rabies vaccine and the human Japanese encephalitis vaccine[66]. - The company’s innovative approaches in vaccine technology, such as the use of VLP technology, are expected to improve the safety and efficacy of its vaccine products[106]. Sales and Marketing - User data indicates that the company has expanded its customer base by 20% in the last year, reaching a total of 5 million active users[26]. - The company has a strong domestic sales team of nearly 300 professionals, covering all provinces and regions in China, and an international sales network in over 30 countries[128]. - The company is enhancing its marketing network and expanding its sales team to improve market penetration and brand recognition[139]. - The company has established strict management protocols for third-party promotional agencies and overseas distributors to mitigate risks[140]. Audit and Compliance - The company has received a standard unqualified audit opinion from Rongcheng Accounting Firm[7]. - The company has not reported any special arrangements for corporate governance[9].